African Americans more likely to exhibit negative perceptions of cancer-related clinical trials
the ONA take:
According to new findings that will be presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, researchers from Fox Chase Cancer Center and Temple University in Philadelphia, Pennsylvania, have found that African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
For the study, researchers identified 41 African Americans with an average age of 60 years. Of those, 54% had no enrolled in a clinical trial within the past 9 months.
Researchers found that non-participants believed that a clinical trial would make them sicker, that important information would be withheld from them, and that no one discussed clinical trial participation with them.
Those who participated in clinical trials felt their doctor had provided enough information in order to make an informed decisions about clinical trial participation and that trials offered the best possible treatment for their disease.
The findings suggest that African American patients with cancer should received detailed information regarding clinical trial participation and their treatment options.
African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|